Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA approves new high dose Spinraza regimen for SMA

 April 1, 2026

PharmaTimes

Updated dosing offers meaningful clinical benefit

RegulatoryRare DiseaseRead full story

Post navigation

Viridian reports positive results from elegrobart phase 3 trial →
← Ambrosia adds a megaround for obesity drugs

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com